Lv3
278 积分 2022-07-27 加入
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
4天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
4天前
已完结
First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial
4天前
已完结
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
4天前
已完结
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
5天前
已完结
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
5天前
已完结
Squamous-Cell Carcinoma of the Lung
5天前
已完结
Nutrient-gene therapy as a strategy to enhance CAR T cell function and overcome barriers in the tumor microenvironment
7天前
已完结
The NOTCH–FOXM1 Axis Plays a Key Role in Mitochondrial Biogenesis in the Induction of Human Stem Cell Memory–like CAR-T Cells
18天前
已完结
Mannose metabolism reshapes T cell differentiation to enhance anti-tumor immunity
1个月前
已完结
皖公网安备34019202002308
